Form 4: Select Medical Grants 20,000 Restricted Shares to CAO

Select Medical Holdings Corp. granted 20,000 shares of restricted common stock to Chief Accounting Officer Christopher Weigl, vesting in 2029.

Summary

• Christopher Weigl, Chief Accounting Officer of Select Medical Holdings Corp. (SEM), was granted 20,000 shares of common stock.
• The transaction occurred on October 28, 2025.
• These shares are restricted stock, which will vest in full on October 28, 2029, the fourth anniversary of the grant date.
• Following this transaction, Mr. Weigl beneficially owns 54,254 shares of common stock.
• The grant price was $0, indicating it was an equity award.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a key executive is a positive signal for executive retention and alignment of interests, contributing to stable management. No negative financial or operational news is present.

Positives

• The grant of 20,000 restricted shares to the Chief Accounting Officer aligns his interests with long-term shareholder value.
• The vesting schedule over four years encourages retention and sustained performance from a key executive.

Risks

• The reporting person remains responsible for compliance with Exchange Act obligations, including Section 16 reporting requirements, despite the Power of Attorney.
• Neither the company nor the attorney-in-fact assumes liability for the reporting person's compliance or profit disgorgement under Section 16(b).

Future Outlook

The grant of restricted stock with a four-year vesting period indicates a long-term commitment to the Chief Accounting Officer, aligning his incentives with the company's future performance through October 2029.

Management Comments

• This Power of Attorney authorizes, but does not require, such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information.
• This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

Industry Context

This transaction is a standard form of executive compensation within the healthcare services industry, aiming to retain key talent and align management interests with long-term shareholder value through equity awards.

Comparison to Industry Standards

• The grant of restricted stock to a Chief Accounting Officer is a common practice in publicly traded companies across various industries, including healthcare.
• While specific comparable companies or projects are not detailed in this filing, such equity awards are generally benchmarked against peer groups to ensure competitive compensation and retention.
• The four-year vesting schedule is also a typical duration for such long-term incentive plans.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive, as executive compensation aligns management interests with long-term shareholder value.
• Employees: No direct impact mentioned, but a stable executive team can contribute to overall company stability.
• Management: Christopher Weigl benefits from increased equity ownership and long-term incentive.

Next Steps

• The restricted stock will vest in full on October 28, 2029.
• Christopher Weigl will continue to comply with Section 16 reporting obligations, potentially through his attorney-in-fact, John F. Duggan.

Key Dates

Recommendation

This Form 4 filing reports a routine restricted stock grant to a key executive, which is a standard component of executive compensation designed for retention and alignment of interests. While positive for executive incentives, it does not present new information that would fundamentally alter the company's financial outlook or warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Select Medical Holdings Corp, SEM, Christopher Weigl, Chief Accounting Officer, Restricted Stock Grant, Equity Compensation, Insider Transaction, Form 4, Executive Compensation